Skip to content

In the Know: Key Abstracts from the American Society of Hematology 2021 Annual Meeting in Acute Lymphoblastic Leukemia
***Poster 2 Pre-assessment***

Before you view the poster session, please take this pre-assessment. Taking this pre-assessment does not immediately qualify learners to earn credit. 

Certificates of credit will only be sent to learners who also receive a passing score on the post-test (separate from this survey), and fill out the evaluation form and application for credit.
1.What are your credentials? (Required.)
2.What is your specialty?
3.How confident are you in the management of patients with ALL in your practice?
Very confident
Confident
Neutral
Little confidence
No confidence
4.Incorporation of blinatumomab into the treatment strategy for front-line therapy of high risk-disease in adult patients with Philadelphia chromosome negative ALL and in children and adolescents/young adults with low-risk, first relapse ALL demonstrated which of the following?(Required.)
5.WA is a 12-year-old girl diagnosed with B-cell ALL 3 years ago with a first isolated marrow relapse after completing maintenance therapy. She is MRD negative after reinduction on AALL1331. 

Which of the following should be incorporated into management of WA?(Required.)
6.Compared with chemotherapy as post-reinduction therapy in low-risk, first relapse of B-cell ALL in children and adolescents/young adults, which of the following best reflects outcomes associated with the incorporation of blinatumomab?(Required.)
7.Please let us know who you are so we can connect your responses to your post-test & application to claim CME credit (completed after participating in the activity) 
Privacy & Cookie Notice